Search Results 1081-1090 of 17884 for Assay

1. Testing Teclistamab (TECVAYLI) In Combination With Iberdomide For Hard-to-Treat Multiple Myeloma - Mayo Clinic

   * Serum free light chain (FLC) assay: "involved" FLC level ≥ 10 mg/dL ( ≥ 100 mg/L) and an abnormal serum free light chain ratio ( \< 0.26 or \> 1.65) * ...

2. A Study to Evaluate the Effect of Olorinab on Gastrointestinal Transit in Patients with Irritable Bowel Syndrome - Mayo Clinic

   Unable to withdraw the following medications that alter GI transit for 72 hours prior to baseline colonic transit assay through the duration of treatment ...

3. Study to Evaluate the Effectiveness and Safety of Remdesivir in Participants with Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 - Mayo Clinic

   ... assay (e.g., Nucleic Acid Amplification Test [NAAT] and antigen tests) in any respiratory specimen. Hospitalized for COVID-19. Age ≥ 12 years and weighing ...

4. Study of bb2121 in Multiple Myeloma - Clinical Trials

   Serum free light chain (FLC) assay: involved FLC level greater or equal to 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal. For Part A (Dose ...

5. Aplastic anemia - Diagnosis & treatment - Mayo Clinic

   Your body stops producing enough new blood cells in this rare and serious condition, possibly causing fatigue, higher risk of infections and uncontrolled ...

6. Publications - Qun Lu, M.D. - Mayo Clinic

   Performance of an automated solid-phase red cell adherence system compared with that of a manual gel microcolumn assay for the identification of antibodies ...

7. Phase Transitions: Ph.D. Students Explore Real-Time Seizure Detection and Antibiotic Resistance - News Archive

   While assays exist to detect and identify the presence of microbes, the tests can be negative, making it challenging to determine if a patient has an infection.

8. A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination with FOLFIRI and Bevacizumab for Second-Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS Mutation - Mayo Clinic

   ... assays. Submission of the tissue does not have to occur prior to enrollment. Signed informed consent to provide blood sample(s) for specific correlative assays.

9. Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair - Mayo Clinic

   ... assay are not eligible to participate unless they also have MMR testing by IHC and are found to have dMMR (i.e. loss of one or more MMR proteins); Patients ...

10. A Study to Evaluate Lenalidomide and Dexamethasone, with or without Daratumumab, in Treating High-Risk Smoldering Myeloma Patients - Mayo Clinic

    Abnormal serum free light chain (FLC) ratio of involved to uninvolved >20, but less than 100 if the involved FLC is >10 mg/dL by serum FLC assay;; Serum M ...